Background: Promoting the neuroprotective and repair-inducing effector functions of microglia and macrophages, by means of M2 polarisation or alternative activation, is expected to become a new therapeutic approach for central nervous system (CNS) disorders in which detrimental pro-inflammatory microglia and/or macrophages display a major contribution to the neuropathology. In this study, we present a novel in vivo approach using intracerebral grafting of mesenchymal stem cells (MSC) genetically engineered to secrete interleukin 13 (IL13-MSC).
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Results: In the first part of this study, we demonstrate that MSC graft-associated microglia and MSC graft-infiltrating macrophages are forced into alternative activation upon grafting of IL13-MSC, but not upon grafting of control MSC. In the second part of this study, we demonstrate that grafting of IL13-MSC, in addition to the recruitment of M2 polarised macrophages, limits cuprizone-induced microgliosis, oligodendrocyte death and demyelination.
Furthermore, we here demonstrate that injection of IL13-MSC at both sides of the splenium leads to a superior protective effect as compared to a single injection at one side of the splenium.
Conclusions: Controlled and localised production of IL13 by means of intracerebral MSC grafting has the potential to modulate cell graft-and pathology-associated microglial/macrophage responses, and to interfere with oligodendrocyte death and demyelinating events in the cuprizone mouse model.
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Background
Detrimental inflammatory responses in the central nervous system (CNS) are a hallmark of various neurodegenerative pathologies, with multiple sclerosis (MS), stroke and traumatic brain or spinal cord injury being excellent examples of the complex interplay between CNS-resident microglia and lesion-infiltrating leukocytes [1] [2] [3] [4] . Although microglia and CNS-invading peripheral monocytes both act as phagocytic cells of the brain, it is currently becoming accepted that these two cell types are more distinct than generally assumed [2, 5] . This is supported by observations in various models of neuroinflammation in which microglia and bone marrow (BM)-derived macrophages may be present at different time points, may have a different spatial distribution and, more importantly, may display different functions and/or phenotypes during the course of neuroinflammation and neurodegeneration [5] . Nevertheless, in the early stage of neuroinflammatory responses, lesion-associated microglia and/or macrophages are generally described as 'classically or M1 activated' , i.e. displaying a phenotype and function comparable to in vitro LPS-and/ or IFNγ-activated macrophages [6] . M1 activated macrophages are thus highly pro-inflammatory and cytotoxic, with their main effector functions being the destruction and removal of damaged or infected cells. From an emerging therapeutic point of view, it is suggested that forced 'alternative or M2 activation' of lesion-associated microglia and/or macrophages during the development of inflammatory responses can have a beneficial effect on disease outcome [5] . M2-activated macrophages are thus suggested to be anti-inflammatory, with their main effector functions being protection and regeneration of injured or diseased tissue. Although dependent on the stimuli applied, several directions of alternative macrophage activation can be achieved in vitro and in vivo [6] . In this study, we aimed to investigate the potential of interleukin 13 (IL13) [7] to modulate microglia and/or macrophage activation in vivo in an attempt to influence pathology-associated neuroinflammation.
One of the major challenges in current CNS immunomodulation research is how to effectively deliver therapeutic proteins (in casu IL13) directly to the site of neuroinflammation. While several methods of delivery can be implemented [8] , including (i) direct protein injection, (ii) non-viral and viral gene therapy and (iii) implantation of genetically engineered cellular grafts, each of them has specific advantages and disadvantages. Whereas direct protein injection would be the most straightforward, it would require multiple injections as, in the case of IL13, sustained therapeutic protein expression may be essential. Alternatively, mechanical or chemical methods (e.g. electroporation, ultrasound or lipoplexes) may be applied to transfer plasmid DNA encoding the therapeutic protein of interest into inflammatory cells at the site of neuroinflammation. Nevertheless, these techniques are still poorly efficient and need further optimisation for in vivo application. On the other hand, gene transfer in the CNS by means of viral vectors is highly efficient in rodents but remains controversial in terms of clinical translation to humans, despite many efforts undertaken to control gene insertion, protein expression and/or unwanted immune reactions. Lastly, transplantation of genetically engineered (stem) cell populations is an emerging methodological approach for in situ delivery of therapeutic proteins [9, 10] . Preceding work by our group has already extensively compared the in vivo behaviour of neural stem cell (NSC) and mesenchymal stem/ stromal cell (MSC) grafts upon implantation in the CNS of mice [11] [12] [13] [14] [15] [16] . Based on our published reports, we have a strong preference for MSC as a cellular carrier to deliver therapeutic proteins due to their relatively easy ex vivo culture, susceptibility for genetic modification and their more robust survival upon grafting in CNS tissue compared to NSC. In this study, we aim to investigate whether in situ grafting of MSC genetically engineered to express IL13 can influence neuroinflammatory responses, both on the level of cell graft-associated inflammatory responses and on the level of pathology-associated inflammatory responses.
In order to address these questions, we investigated the behaviour of control MSC and IL13-expressing MSC grafts both under healthy and under inflammatory CNS conditions. For the latter, we used the well-established cuprizone (CPZ) mouse model of CNS inflammation, oligodendrocyte death and subsequent demyelination [17] . Furthermore, in order to separately investigate the behaviour of brain-resident microglia and CNS-invading peripheral macrophages, part of the experiments presented in this study were performed in the CX 3 eGFP/ eGFP mice with CCR2 RFP/RFP mice. During the entire study, the mice were kept in the animalarium of the University of Antwerp (UA) under normal day-night cycle (12/12) with free access to food and water. All animal experimental procedures were approved by the Ethics Committee for Animal Experiments of the UA (approval no. 2011-13 and 2012-39).
Lentiviral vector production
The pCHMWS-IL13-IRES-Pac lentiviral vector (LVv) plasmid was constructed by replacing the eGFP cDNA insert (SpeI/XbaI digest) from the pCHMWS-eGFP-IRES-Pac plasmid (provided by the Leuven viral vector core, Molmed, KULeuven, Belgium) with the IL13 cDNA (NcoI/NheI digest) from the pORF-mIL13 plasmid (InvivoGen) using standard subcloning techniques. Before proceeding to LVv production, the pCHMWS-IL13-IRES-Pac plasmid was electroporated in K562 cells followed by stable selection by addition of puromycin to the culture medium. Expression of IL13 was confirmed by a murine IL13 ELISA (Peprotech) using the supernatant of stably transfected puromycinresistant K562 cells. Following confirmation of IL13 expression and Pac functionality, LVv production was outsourced to the Leuven viral vector core [18, 19] .
Culture and genetic engineering of MSC
In this study, we used a previously established and characterised C57BL/6 mouse BM-derived MSC line (further named as parental MSC) [20] and a derivative thereof, genetically engineered to express the blue fluorescent protein (further named as blue fluorescent protein (BFP)-MSC) [13] . For expansion, both MSC lines were cultured in standard cell culture plasticware (well plates and/or culture flasks) in 'complete expansion medium' (CEM) [21] consisting of Iscove's modified Dulbecco's medium (IMDM; Lonza) supplemented with 8% fetal bovine serum (FBS; Invitrogen), 8% horse serum (HS; Invitrogen), 200U/ml + 100 μg/ml penicillin/streptomycin (Invitrogen) and 1 μg/ ml amphotericin B (Invitrogen). Culture medium for BFP-MSC was further supplemented with 1 μg/ml puromycin (InvivoGen). MSC cultures were split 1:5 twice a week using 0.05% trypsin-EDTA (Invitrogen) for cell detachment. Both the parental MSC line and the BFP-MSC line were transduced with the pCHMWS-IL13-IRES-Pac LVv, according to previously optimised procedures [13, 21] . Following puromycin selection, the resulting engineered MSC lines were further named as IL13-MSC and IL13/BFP-MSC. Culture medium for both IL13-MSC and IL13/BFP-MSC was further supplemented with 5 μg/ml puromycin. 
Bone marrow transplantation experiments
In order to discriminate between microglia and macrophages, eGFP + BM chimaeric mice were generated as previously described [13] . Briefly, wild-type C57BL/6 mice received 10Gy total body irradiation using an XRAD320 small animal irradiation device (Precision X-Ray). For this, groups of five non-anesthetised mice were placed in a single cage within the whole irradiation field (without head protection). Six hours post-irradiation, a single intravenous injection of total eGFP + BM cells (1.5 × 10 6 cells in 100 μl phosphate buffered saline) was administered via the tail vein. Total BM cells were isolated from 8-weekold C57BL/6-eGFP mice by flushing dissected femurs and tibias with sterile phosphate buffered saline (PBS). Before administration, total BM cells were filtered over a 70-μm sterile mesh (Becton Dickinson), centrifuged and suspended in PBS. During recovery, mice were treated with enrofloxacin (1 μl/ml; Baytril 10%; Bayer) added to the drinking water for 8 weeks post-irradiation.
Cell implantation experiments
All surgical experiments were performed under sterile conditions, as previously described [22] [23] [24] . Briefly, mice were anesthetised by an intraperitoneal injection of a ketamine (80 mg/kg, Pfizer) + xylazine (16 mg/kg, Bayer Health Care) mixture in PBS and placed in a stereotactic frame (Stoelting). A midline scalp incision was made and a hole was drilled in the skull using a dental burr drill (Stoelting) at the following coordinates relative to bregma: (i) 2.3 mm dextra for injections in healthy mice, or (ii) 0.3 mm dextra at 1.6 mm posterior for injections in CPZ-treated mice or (iii) 0.3 mm dextra and 0.3 mm sinistra at 1.6 mm posterior for double injections in CPZ-treated mice. Next, an automatic microinjector pump (kdScientific) with a 10 μl Hamilton syringe was positioned above the exposed dura. A 30-gauge needle (Hamilton), attached to the syringe, was placed through the intact dura to a depth of 2.3 mm for injections in healthy mice (directly underneath the capsula externa) and to a depth of 1.3 mm in CPZ-treated mice (directly within the right side or both left and right sides of the splenium of the corpus callosum). After 2 min of pressure equilibration, a suspension of 2 × 10 4 MSCs in a volume of 0.4 μl was injected in CPZ-treated mice or a suspension of 2 × 10 5 MSCs in a volume of 2 μl was injected in healthy mice. The needle was retracted after another 4 min to allow pressure equilibration and to prevent backflow of the injected cell suspension. Next, the skin was sutured (Vicryl, Ethicon) and 100 μl of a 0.9% NaCl solution (Baxter) was administered subcutaneously in order to prevent dehydration while mice were placed under a heating lamp to recover.
Cuprizone mouse model
For induction of CNS inflammation and demyelination, mice received standard rodent chow mixed with 0.2 % w/w CPZ (Sigma-Aldrich) for 4 weeks between the ages of 8 and 12 weeks, as previously described [14, [25] [26] [27] .
Magnetic resonance imaging acquisition
For the first study setup, in which a single injection on the right side of the splenium was performed in CPZ-treated mice, in vivo imaging experiments were conducted at 400 MHz on a 9.4T Bruker Biospec system (Biospec 94/20 USR, Bruker Biospin) using a standard Bruker cross coil setup, with a quadrature volume coil for excitation and a quadrature mouse surface coil for signal detection. For the second study setup, in which a double injection on both the right side and the left side of the splenium was performed in CPZ-treated mice, in vivo imaging experiments were conducted at 400 MHz on a 7T Pharmascan MR scanner (Bruker, Germany). This system is equipped with a standard Bruker cross coil setup, with a quadrature volume coil for excitation and an array mouse surface coil for signal detection. During imaging, mice were anesthetised using 2% isoflurane (Isoflo®, Abbot Laboratories Ltd.) in a mixture of 30% O 2 and 70% N 2 O at a flow rate of 600 ml/min. Mice were fixed in an animal restrainer with ear bars and a tooth bar. Respiratory rate was continuously monitored, and body temperature was measured and maintained constant at 37°C using a feedback coupled warm air system (MR compatible Small Animal Monitoring and Gating System, SA instruments, Inc.). T 2 values were acquired with the multi-slice multi-echo (MSME) sequence that is based on the Carr-Purcell-Meiboom-Gill (CPMG) sequence, where transverse magnetization of a 90°pulse is refocused by a train of 180°pulses generating a series of echoes. For the study setup with a single injection on the right side of the splenium, the following imaging parameters were used: number of averages ( 
Magnetic resonance imaging processing
T 2 maps were generated with custom-built programmes written in MATLAB (MATLAB R2011b, The MathWorks Inc.) using a monoexponential fit function [y = A + C*exp (−t/T 2 )], where A = absolute bias, C = signal intensity and T 2 = transverse relaxation time. Regions of interest (ROIs) were drawn manually on the T 2 -weighted images, according to a mouse brain atlas, with AMIRA software (Mercury Computer systems) and regional average T 2 values were calculated. ROIs included the external capsule (EC) and the splenium of the corpus callosum (CC), which was further divided in two parts in respect to the brain's midline and later referred as the right and the left sides of the splenium.
Immunofluorescence analysis
All immunofluorescence analyses were performed according to previously described procedures [22, 23] . Mice were transcardially perfused with 0.9 % NaCl solution followed by 4% paraformaldehyde (PFA) solution. Next, brains were isolated and further fixed in 4 % PFA for 3 h, then dehydrated through a sucrose gradient of 5, 10 and 20 %. Afterwards, brain tissue was snap-frozen in liquid nitrogen and kept at −80°C until further processing. Ten-micrometer-thick cryosections were made using a microm HM500 cryostat. Immunofluorescence staining was performed on brain slides using the following antibody combinations: a primary goat anti-MBP antibody (1 μg/ml, Santa Cruz, sc-13914) with a secondary donkey anti-goat Alexa Fluor 350 antibody (20 μg/ml, Invitrogen,A21081); a primary rabbit anti-Iba1 antibody (1 μg/ml, Wako, 019-19741) with a secondary donkey anti-rabbit Alexa Fluor 555 (2 μg/ml, Invitrogen, A31572); a primary rabbit anti-GFAP antibody (4.5 μg/ml, Abcam, ab7779) with a secondary donkey anti-rabbit Alexa Fluor 555 antibody; a primary rat anti-F4/80 antibody (4 μg/ml, AbD serotec, MCA497GA) with a secondary goat anti-rat Cy5 antibody (10 μg/ml, Invitrogen, A10525); a primary rat anti-MHCII antibody (2.5 μg/ml, eBioscience, 14-5321-82) with a secondary goat anti-rat Alexa Fluor 555 or goat anti-rat Alexa Fluor 350 antibody (10 μg/ml, Invitrogen, A21093); a primary goat anti-Arg1 antibody (2 μg/ml, Santa Cruz, sc-18354) with a secondary donkey anti-goat Alexa Fluor 555 (10 μg/ml, Invitrogen, A21432) or donkey anti-goat Cy5 antibody (10 μg/ml, Abcam, AB6566); a primary rabbit anti-Ym1 antibody (0.4 μg/ml, Stemcell Technologies, 01404) with a secondary donkey anti-rabbit Alexa Fluor 555 antibody; a primary chicken anti-MBP antibody (0.5 μg/ml, Millipore, AB9348) with a secondary donkey anti-chicken Cy3 antibody (7.5 μg/ml, Jackson Immunoresearch, JIR703-166-155); and a primary mouse anti-CC1 antibody (0.5 μg/ml, Millipore, OP80) with a secondary goat anti-mouse Alexa Fluor 555 antibody (10 μg/ml, Invitrogen, A21425).
Histological quantification
Quantitative phenotypic analyses of microglia and macrophage and responses following MSC grafting in bone marrow chimaeric mice were performed using TissueQuest immunofluorescence analysis software (TissueGnostics GmbH, v3.0), as previously described by our group [12, 13, 15, 23] . Briefly, for each of the slides analysed, the MSC graft site was manually delineated based on nuclear TOPRO-3 staining. The MSC graft site border was then determined as a region extending 85 μm from the MSC graft site. According to previously established procedures, the following parameters were determined: the cellular density of (i) eGFP + macrophages (three slides per cell graft analysed), (ii) MHCII + eGFP + macrophages (one slide per cell graft analysed), (iii) Arg1 + eGFP + macrophages (one slide per cell graft analysed), (iv) Iba1 + cells (one slide per graft analysed) and (v) MHCII + Arg1 + cells (one slide per cell graft analysed). Quantitative analyses of microglial inflammation and/or demyelination in the cuprizone mouse model were performed using NIH ImageJ analysis software (v1.47), according to previously established procedures [13, 15, 23] . Briefly, the following parameters were determined for the whole splenium and the right and the left sides of the splenium: (i) percentage of eGFP coverage (three slides per mouse brain analysed) and (ii) percentage of MBP coverage (one to three slides per mouse brain analysed). In addition, the cellular density of CC1 + oligodendrocytes was determined using TissueQuest software (one slide per mouse brain analysed).
Statistical analyses
For the results obtained following MSC implantation in the CNS of healthy eGFP + bone marrow chimaeric mice, the following statistical analyses were applied. (i) Differences in cellular density of MHCII-and Arg1-expressing eGFP − microglia and eGFP + macrophages within the implant site and the implant border of BFP-MSC and IL13-MSC grafts were analysed using Wilcoxon tests. (ii) Differences in cellular density of all subgroups present in the implant site and the implant border of BFP-MSC and IL13-MSC grafts, based on eGFP, MHCII and Arg1 expression were analysed using Wilcoxon tests. However, because groups were very small (n = 5 or 6), the p value produced by this test is bounded by a non-significant minimal value. We therefore used t tests when normality was not rejected. We here rely on the normality assumption, since normality tests suffer from low power in this low sample size setting. p values were corrected for multiple testing using the false discovery rate method [28] . For the results obtained following MSC grafting in the cuprizone mouse model, the following statistical analyses were applied. (i) Comparisons of mean T 2 -relaxation times of the left, right and whole splenium of the CC, and the EC between healthy mice, CPZ-treated mice, BFP-MSC grafted CPZ-treated mice and IL13-MSC grafted CPZ-treated mice (right side injection) were analysed using a two-way ANOVA, with the obtained p values being corrected for multiple testing using the Tukey HSD post hoc test. In this way, possible differences between the three experiments are taken into account. (ii) Comparisons of mean T 2 relaxation times of the left, right and whole splenium, and the EC between healthy mice, CPZ-treated mice and IL13-MSC injected mice (right and left side injection) were analysed using non-parametric Wilcoxon tests, with the given p values being corrected for multiple testing using the false discovery rate method. (iii) Comparisons of the percentages of eGFP and MBP coverage in the left, right and whole splenium of CX 3 CR1 eGFP/+ CCR2 RFP/+ mice between healthy mice, CPZ-treated mice, BFP-MSC grafted CPZ-treated mice and IL13-MSC grafted CPZtreated mice (right side injection) were analysed by using GEE, with the given p values being corrected for multiple testing using the false discovery rate method [29] . (iv) Comparisons of MBP coverage percentages and CC1+ cell density in the left, right and whole splenium between healthy mice, CPZ-treated mice and IL13-MSC injected mice (right and left side injection) were analysed using a Wilcoxon rank sum test, with the given p values being corrected for multiple testing using the false discovery rate method. 
Results
Transplantation of IL13 producing MSC in the CNS locally induces expression of markers associated with alternative activation in microglia and macrophages
In the first part of this study, we investigated whether microglia, macrophage or astrocyte behaviour was altered upon implantation of IL13-producing MSC (n = 5) as compared to implantation of control blue fluorescent protein (BFP)-expressing MSC (n = 6) in the CNS of healthy mice. In order to discriminate between microglia and macrophages, BFP-MSC and IL13-MSC were grafted in eGFP + bone marrow chimaeric mice, and MSC grafts were histologically analysed at day 10 post-grafting. As shown by the representative immunofluorescence images in Fig. 1a , a GFAP + astroglial scar delineates both BFP-MSC and IL13-MSC grafts. No noticeable differences were observed at the level of astroglial scarring. Within the MSC graft site, a clear side-by-side presence of grafted BFP-MSC or IL13-MSC ( Fig. 1b; arrowheads) and eGFP + BM-derived peripheral macrophages ( Fig. 1b; arrows) can be noted. As expected, the majority of BFP-MSC and IL13-MSC graft-invading eGFP + peripheral macrophages reside within the astroglial scar (Fig. 1a) . However, upon IL13-MSC grafting, the location of eGFP + BM-derived macrophages seems to be less restricted to the implant site as compared to BFP-MSC grafts (Fig. 1a) . In this transplantation model, microglia and macrophages can be distinguished following Iba1 staining (Fig. 1c) . As shown, the majority of Iba1 + cells within both the BFP-MSC and the IL13-MSC grafts are eGFP + macrophages ( Fig. 1c; arrows) , whereas the majority of Iba1 + cells within the implant border are eGFP − microglia ( Fig. 1c; arrowheads). Further quantification indeed confirms that the density of eGFP + macrophages is higher within both the BFP-MSC and the IL13-MSC graft as compared to the graft-surrounding border (both p < 0.0001). However, more Iba1 + eGFP + macrophages are found in the implant border in the case of IL13-MSC grafts as compared to BFP-MSC grafts (p = 0.0121). For graphical representation of these results, see the description of Fig. 2c . In order to further investigate differences between BFP-MSC and IL13-MSC graft-associated microglia and macrophages, we performed additional immunofluorescence stainings to determine the expression of the activation markers MHCII and arginase1 (Arg1). MHCII expression could be detected on eGFP + macrophages and eGFP − microglia within both MSC grafts (Fig. 1d , indicated by arrows and arrowheads, respectively).
Furthermore, while MHCII expression was rarely detected on eGFP + macrophages and eGFP − microglia in the border of BFP-MSC grafts (Fig. 1d , indicated by arrows and arrowheads, respectively), its expression is clearly visible on both eGFP + macrophages and eGFP − microglia in the border of IL13-MSC grafts (Fig. 1d , indicated by arrows and arrowheads, respectively). Further quantification provided in Fig. 1e confirms that the highest density of MHCII + cells can be detected among eGFP + macrophages and eGFP − microglia within the BFP-and IL13-MSC grafts, without significant differences between both graft types (Fig. 1e) . However, the density of MHCII + eGFP + macrophages and MHCII + eGFP − microglia in the IL13-MSC graft border is significantly higher than in the BFP-MSC graft border (Fig. 1e , both p = 0.0346). Next, we found that Arg1 was not expressed on eGFP + macrophages or eGFP − microglia within or surrounding the BFP-MSC grafts (Fig. 1f) (Figs. 2b,  c) . While Fig. 2b indicates each individual microglia and macrophage subpopulations directly compared between implant site and implant border of BFP-MSC and IL13-MSC grafts, Fig. 2c provides overview pie charts for overall comparison of the differences between BFP-MSC and IL13-MSC grafts. Note the following important similarities and/or differences: (i) macrophages are the major immune cell population within the BFP-and IL13-MSC grafts; (ii) microglia are the major immune cell population surrounding the BFP-and IL13-MSC grafts; (iii) the number of macrophages surrounding the IL13-MSC grafts is significantly higher than the number of macrophages surrounding the BFP-MSC grafts (see above; p = 0.0121); (iv) around 50% of macrophages within the BFP-MSC grafts express MHCII, while the majority (80 %) of macrophages within the IL13-MSC grafts express Arg1 with half of them co-expressing MHCII; (v) the small population of microglia within the BFP-MSC grafts expresses MHCII, whereas microglia within the IL13-MSC grafts display a heterogeneous expression of MHCII and/or Arg1; (vi) in the BFP-MSC graft border, only a small population of microglia and macrophages express MHCII; and (vii) in the IL13-MSC graft border, the majority of both microglia and macrophages display a heterogeneous expression of MHCII and/or Arg1. Overall, these results indicate that IL13 secretion by MSC grafts induces a broad spectrum of alternatively activated brain-resident microglia and graftinfiltrating peripheral macrophages, both within and around the MSC graft.
Non-invasive T 2 -weighted MRI reveals a protective effect against CPZ-induced CNS inflammation and demyelination following grafting of IL13-producing MSC Next, we investigated whether grafting of IL13-producing MSC, and the subsequent secretion of IL13 and/or the appearance of M2 polarised microglia and macrophages, could influence neuroinflammatory responses. For this, we performed three independent experiments of which the details of employed mouse strains (wt C57BL/6 or C57BL/6 CX 3 CR1 eGFP/+ CCR2 RFP/+ mice), grafted cell types (BFP-MSC, IL13-MSC or IL13/BFP-MSC) and size of the different experimental groups (healthy control, CPZ control, CPZ + BFP-MSC and CPZ + IL13-MSC) are provided in Table 1 . Experimentally, 8-week-old mice received a BFP-MSC or an IL13-MSC graft at the right side of the splenium of the corpus callosum followed by a 4-week CPZsupplemented diet. Healthy control mice were kept on normal rodent diet for 4 weeks, while CPZ control mice received a 4-week CPZ-supplemented diet without undergoing surgical intervention. At the age of 12 weeks, T 2 -weighted MRI was applied to non-invasively measure CPZinduced inflammation and demyelination in the splenium and the external capsule (EC, internal control region) [30] . As no significant differences in the calculated T 2 relaxation times for the splenium and the EC were found between wt C57BL/6 (used in experiments 1 and 2) and C57BL/6 CX 3 CR1 eGFP/+ CCR2 RFP/+ mice (used in experiment 3), under both healthy conditions as well as under CPZ treatment, data from all three experiments were used to increase power in further statistical analyses (Fig. 3a, b , experiment 2 versus experiment 3, healthy control and CPZ control). When comparing the calculated T 2 relaxation time for the whole splenium (both right and left sides of the midline) and the whole EC (both right and left sides) from healthy control mice and non-injected CPZtreated mice (CPZ control), it is clear that CPZ treatment causes a significant increase of the T 2 relaxation time in both brain regions (Fig. 3a, b , for both p < 0.0001). This can also be noted on the representative MRI images provided where hyperintensity regions were seen in the splenium and EC of CPZ control mice, a finding not observed in healthy control mice (Fig. 3a, b) . When comparing the T 2 relaxation times of the whole splenium in BFP-MSC with IL13-MSC grafted mice, data indicate that T 2 relaxation times of IL13-MSC grafted mice, but not of BFP-MSC grafted mice, deviate significantly less from healthy control values compared to those obtained from CPZ-treated mice (Fig. 3a , CPZ control versus CPZ + IL13-MSC, p = 0.0007). This is indicative of reduced inflammation and demyelination in the splenium of IL13-MSC grafted mice. The latter can also be noted on the representative MRI images provided in Fig. 3a , where the splenium in IL13-MSC grafted mice displays less hyperintensity as compared to CPZ control mice. The observation that T 2 relaxation times of the EC remained high and were not significantly different from those obtained in CPZ control mice (Fig. 3b) indicates that the observed protective effect following grafting of IL13-MSC is due to the performed cell therapeutic intervention and does not result from model failure and/or model variation. Of note, we observed in some of the BFP-MSC grafted mice that this procedure might have led to neuroprotection. However, as this was only observed in part of the mice from one out of three MRI experiments, the results convince that IL13-MSC grafting is superior to control BFP-MSC grafting in establishing protection against inflammation and demyelination in the whole splenium. Further analyses over the right and left sides of the splenium by T 2 -weighted MRI indicates that the protective effect of grafting IL13-expressing MSC is of higher significant importance on the right side of the splenium (p < 0.0001) as compared to the left side of the splenium (p = 0.01) (Fig. 3c, d ).
Histological evaluation confirms protection against CPZinduced CNS inflammation and demyelination by IL13-secreting MSC
Next, we performed immunofluorescent stainings for myelin basic protein (MBP) on C57BL/6 CX 3 CR1 eGFP/+ CCR2 RFP/+ mice for which MRI data were obtained (MRI experiment 3, n = 5 for healthy control, n = 5 for CPZ control, n = 5 for CPZ + BFP-MSC and n = 7 for CPZ + IL13-MSC), and assessed both the degree of CX 3 CR1 eGFP/+ microglia activity (as determined by the percentage of eGFP coverage) and the degree of myelination (as determined by the percentage of MBP coverage) in the whole splenium, the right side of the splenium and the left side of the splenium (Fig. 4) . As shown by the representative images in Fig. 4a , it is clear that the splenium becomes highly invaded by CX 3 CR1 eGFP/+ microglia following CPZ treatment. As expected from the abovementioned MRI data, representative images of IL13-MSC grafted mice show a decrease in CX 3 CR1 eGFP/+ microglia density in the splenium, which was not observed in BFP-MSC grafted mice. In agreement with the aforementioned MRI data, further quantitative analysis of microglia activity (Fig. 4b) within the whole, the right and the left side of the splenium confirms a significant decrease following grafting of IL13-MSC over the whole splenium (p = 0.02), and more specifically at the right side (p < 0.0001) of the splenium, as compared to non-grafted CPZ control mice. In contrast, no overall significant decrease in microglia activity could be detected following grafting of BFP-MSC in the splenium, as compared to non-grafted CPZ control mice. Concerning the degree of myelination, it is clear from the representative images provided in Fig. 4a that severe demyelination can be observed at the site of CX 3 CR1 + microglia accumulation upon CPZ administration. Moreover, as expected from the MRI and representative images of IL13-MSC grafted mice, protection against demyelination of the splenium is suggested. Further quantitative analysis of myelination (Fig. 4c) within the whole, the right and the left side of the splenium confirms a significant protection against demyelination following grafting of IL13-MSC over the whole splenium (p = 0.0011) and the right side of the splenium (p < 0.0001), as compared to non-grafted CPZ control mice. Again, no overall significant protection against demyelination could be detected following grafting of BFP-MSC in the splenium, as compared to non-grafted CPZ control mice.
T 2 -weighted MRI results strongly correlate with histology data
As we have obtained a large set of corresponding MRI and histology data, we investigated if non-invasive T 2 -weighted MRI observations can be used as a reliable surrogate analysis to assess inflammation and demyelination in the CPZ mouse model. When histologically evaluating CX 3 CR1 eGFP/+ microglia density and MBP myelination, a very strong negative correlation (r = −0.789; 95 % confidence interval [−0.91; −0.50]) was found between the microglia density and myelination over the whole splenium (Fig. 4d, left graph) . When evaluating T 2 -weighted MRI data with histological data showing CX 3 CR1 eGFP/+ microglia density, a strong positive correlation (r = 0.635; 95 % confidence interval [0.22; 0.86]) was found between the increase in microglia density and the increase of T 2 relaxation time over the whole splenium (Fig. 4d, middle graph) . When evaluating T 2 -weighted MRI data with histological data showing MBP myelin density, a strong negative correlation (r = -0.650; 95 % confidence interval [−0.84; −0.29]) was found between the decrease in MBP density and the increase of T 2 relaxation time over the whole splenium (Fig. 4d, right graph) . Based on these correlation analyses, we are confident that the observed T 2 -weighted MRI images reflect the obtained histological data. MSC grafted mice, but not BFP-grafted mice, show a remarkable decrease in CX 3 CR1 eGFP/+ microglia density in the whole splenium (Fig. 5 , first and second rows, direct CX 3 CR1-eGFP fluorescence and direct CCR-RFP fluorescence, quantification provided in Fig. 4b ). In agreement with our previously published data on the spatial distribution of microglia and BM-derived macrophages following MSC transplantation in the CNS, and with the data presented in the first part of this manuscript, both MSC graft types in CPZ-treated CX 3 CR1 eGFP/+ CCR2 RFP/+ mice are invaded by CCR2 RFP/+ peripheral macrophages and surrounded by CX 3 CR1 eGFP/+ brain-resident microglia (Fig. 5 , second row, direct CX 3 CR1-eGFP fluorescence and direct CCR2-RFP fluorescence) [13] . Clearly, following MSC grafting in the CPZ model, we can thus distinguish two separate inflammatory responses: on one hand, CPZinduced CX 3 CR1
eGFP/+ microglia activation in the splenium which can be modulated following grafting of IL13-expressing MSC; on the other hand, MSC graft-associated CX 3 CR1 eGFP/+ microglia and CCR2 RFP/+ peripheral macrophage activation. Upon further evaluation of the activation status of microglia and macrophages, by staining for F4/80 in each of the experimental groups, it is clear that CPZ pathology-associated CX 3 CR1 eGFP/+ microglia, as well as MSC graft-associated CX 3 CR1 eGFP/+ microglia and CCR2 RFP/+ peripheral macrophages, express F4/80 (Fig. 5 , third and fourth rows, blue staining), while expression of this activation marker is absent on steady-state resting microglia in healthy brain tissue. MHCII expression is mainly restricted to CCR2 RFP/+ peripheral macrophages invading the BFP-MSC graft, whereas MHCII is expressed on both IL13-MSC graft-infiltrating CCR2 RFP/+ peripheral macrophages and on graft-surrounding CCR2 RFP/+ macrophages and CX 3 CR1 eGFP/+ microglia (Fig. 5 , fifth and sixth rows, blue staining). Also note that no MHCII expression was detected on CPZ pathology-associated CX 3 CR1 eGFP/+ microglia (Fig. 5, fifth and sixth rows) . Finally, staining for Arg1 (Fig. 5, seventh and eighth rows, blue staining) can only be detected on IL13-MSC graftinfiltrating and graft-surrounding CCR2 RFP/+ peripheral macrophages and CX 3 CR1 eGFP/+ microglia. These results indicate that IL13 produced by grafted MSC is able to (i) trigger alternative activation of MSC graft-associated microglia and macrophages also in the diseased brain and (ii) diminish CPZ-induced inflammation and demyelination by its direct action or in combination with the action of alternatively activated macrophages/microglia.
Non-invasive T 2 -weighted MRI reveals that two injections of IL13-expressing MSC results in superior protection against CNS inflammation and demyelination
Given the observation that grafting of IL13-MSC on the right side of the splenium confers histopathological protection only on the right side of the splenium, we next investigated whether grafting of IL13-MSC on both the left and right sides of the splenium could induce a stronger and more widespread effect. In this study, 8-weekold wild-type C57BL/6 mice were divided over three experimental groups: a healthy control group (n = 10) which received a normal rodent diet for 4 weeks, a CPZ control group (n = 10) which received 4 weeks of CPZsupplemented diet without any injections and an IL13-MSC group (n = 10) which received 4 weeks of CPZsupplemented diet and IL13-MSC injections at both the right and left sides of the splenium. First, MRI was applied to non-invasively evaluate CPZ-induced inflammation and demyelination in the splenium and the EC. When evaluating T 2 relaxation times over the whole splenium, it is clear that grafting of IL13-MSC highly significantly (p < 0.0001) prevents deviation from normal T 2 relaxation times upon cuprizone administration (Fig. 6a) . Again, the observed neuroprotection in the splenium is specific to the IL13-MSC grafting procedure as T 2 relaxation times in the EC were equally well affected by the cuprizone diet in both the CPZ control group and the IL13-MSC group (Fig. 6b , for both p < 0.0001). Most interestingly, using this experimental setup we are able to confirm that grafting of IL13-MSC both on the right and left sides of the splenium is superior to a single graft on the right side. When evaluating T 2 relaxation times separately on the left and right sides of the splenium, it is clear that the observed protection is now equally well distributed over both sides of the splenium (Fig. 6c, d ; for all p ≤ 0.0001).
Histological evaluation confirms that reduced demyelination following grafting of IL13-MSC is associated with oligodendrocyte survival in the splenium of CPZ-treated mice
In agreement with our MRI data, histological analysis first confirmed that grafting of IL-13 MSC at both sides of the splenium prevents demyelination over the whole splenium, both at the right and left sides ( Fig. 7a ; IL13-MSC versus CPZ control, p = 0.0045, p = 0.0025 and p = 0.0062, respectively). These results thus further confirm our hypothesis that grafting of IL13-MSC on both the left and right sides of the splenium could induce a stronger and more widespread effect as compared to IL13-MSC grafting only at the right side (Figs. 3 and 4) . Next, we aimed to investigate whether the presence of myelin in the IL13-MSC group could be related to the actual survival/presence of oligodendrocytes. For this, an additional immunostaining for CC1 was performed and the density of CC1 + oligodendrocytes was determined within the whole, left side and right side of the splenium (Fig. 7b) . While CC1 + oligodendrocyte death is highly prominent in the CPZ control group, their survival is highly significant in the whole, left side and right side of the splenium following IL13-MSC grafting at both the left and right sides of the splenium + cell density and T 2 relaxation times (Fig. 7c, right graph) . These correlation analyses again demonstrate that the MRI analyses reflect the obtained histological data.
Discussion
In the first part of this study, we evaluated the use of autologous MSC grafts in the CNS as a delivery vehicle for the immune modulating cytokine IL13. With regard to our choice to use MSC as a delivery vehicle, we previously reported extensively on the cellular remodelling of mesenchymal (stem) cell grafts in the CNS of healthy mice. From these studies, it is now well-accepted that this intervention is a highly complex interplay between hypoxia-induced apoptosis of the grafted cells, neutrophil invasion, neoangiogenesis, microglia/macrophage recruitment, astrogliosis and eventually survival of a significant (5-30%) number of grafted cells [11] [12] [13] [14] [15] 31] . In previous studies, we also reported that graft-recognising microglia/macrophages display a pro-inflammatory phenotype as shown by the temporary expression of CD11b and MHCII. It should be noted however that, at the time of these studies, we were unable to experimentally distinguish brain-resident microglia from CNS-invading macrophages [12] . In this new study, we highlight the potential of IL13 secretion by grafted MSC to induce alternative activation both in MSC graft-surrounding microglia and in MSC graft-infiltrating macrophages in vivo, as indicated by the expression of Arg1 and Ym1 (Fig. 1f-h) . Moreover, from our study it is also clear that IL13 priming of macrophages and microglia in vivo does not result in a single clearly distinguishable cell population (Fig. 2) . We may speculate that each of the microglia or macrophage phenotypes described, either single positive for MHCII, single positive for Arg1 or double positive, may exert a different effector function; however, this remains to be further investigated on the single cell level. Thus far, apart from the induction of markers associated with alternative activation, we currently do not know what influence IL13 and/or M2 polarised microglia/macrophages display on the in vivo survival of autologous MSC grafts and/or their in vivo remodelling. While our first observations do not indicate a major difference between autologous MSC grafts with and without genetic engineering to secrete IL13 (Fig. 1a-e) , we recently reported that transplantation of allogeneic MSC genetically engineered to secrete IL13, with subsequent induction of Arg1, Ym1 and Fizz1 expression in MSC graft-recognising microglia and/ or macrophages, leads to highly reduced downstream effector function in terms of (i) direct in vivo recognition and elimination of allogeneic cellular grafts and (ii) in vivo induction of allogeneic T cell immune responses [32] . Although the process of direct and indirect allorecognition does not occur with autologous (syngeneic) cellular grafts, we may speculate that IL13 can have a beneficial effect on long-term engraftment of autologous MSC grafts in the CNS; however, this needs further investigation.
In the second part of our manuscript, we provide a thorough analysis of MSC graft-mediated IL13 delivery as an effective approach to modulate pathology-associated immune responses in the CNS of mice. We here highlight that IL13 production by grafted MSC, potentially aided by the appearance of alternatively activated microglia and macrophages at the MSC graft site, prevents microgliosis, oligodendrocyte death and demyelination in the CPZ mouse model (Figs. 4 and 7) . Note that the therapeutic approach presented here, i.e. intracerebral grafting of IL13-producing MSC, is significantly different from several previously published reports regarding the therapeutic use of non-engineered MSC in the CPZ mouse model. A study by Nessler and colleagues was unable to report any clinical benefit of both intravenously or intranasally administered MSC [33] , most likely due to limited cell migration to the CNS. In addition, our own preceding work on cell grafting in the CPZ model at the peak of inflammation and demyelination was also unable to demonstrate any contribution of mesenchymal, neural or haematopoietic cells to remyelination [14] . The latter observation was recently confirmed by a study performed by Salinas Tejedor et al. showing that MSC injected at the onset or the peak of oligodendrocyte proliferation during cuprizoneinduced demyelination do not exert beneficial effects on remyelination [34] . Although all these studies question the use of MSC to exert direct neuroprotective effects in the CPZ model, we here provide an alternative approach in which we demonstrate that autologous MSC are wellsuited as transplantable carrier cells for the direct delivery of a therapeutic protein to the injured CNS, as proven in the current study for the M2-polarising cytokine IL13. However, currently still open for debate is the actual working mechanism for the observed neuroprotective character of MSC-mediated IL13 delivery in the CNS. Based on our current knowledge, and in agreement with several literature reports, we propose the following working hypothesis. Previously, it has been described by Yang et al. that IL13 can directly induce apoptosis in activated microglia [35] . It is not unlikely that this feature of IL13 highly contributes to the reduced microgliosis, and subsequent reduced oligodendrocyte death and demyelination, observed in this study. Although we prefer to support this first hypothesis, M2 polarised macrophages/microglia, which are effectively introduced in the CNS by means of local transplantation of IL13-producing MSC, may also indirectly contribute to the observed protection against demyelination. In this context, it has previously been reported that M2 polarised macrophages are able to promote oligodendrocyte differentiation and enhance remyelination [36] . However, using the current experimental setup we cannot make a clear distinction between protection against inflammationinduced oligodendrocyte death and/or already occurred oligodendrocyte regeneration. Likewise, given the intrinsic toxic nature of CPZ to oligodendrocyte metabolism [17] , it remains to be elucidated whether the observed myelin is fully functional on the structural and functional level. For this, electron microscopy [37, 38] and more advanced MRI studies [26, 27, 39] are planned in our future experiments. Nevertheless, as the field of CNS immunomodulation is highly complex and continuously evolving, a highly complex interplay between both proposed mechanisms may not be not unlikely.
Finally, we would like to elaborate a little on the proposed experimental strategies used in this study. First, we applied non-invasive T 2 -weighted MRI (Figs. 3 and 6 ) and correlated these findings with post-mortem histological analyses (Figs. 4 and 7) . Although MRI analyses are not novel for the CPZ mouse model, we here demonstrate that therapeutic interventions in the CPZ mouse model can successfully be detected by means of T 2 -weighted MRI. Therefore, longitudinal MRI studies of the CC in the CPZ mouse model may/should become highly complementary to single point post-mortem histological analyses when applying therapeutic interventions, as previously suggested by us [39] . Second, our MSC implantation approach deserves some special attention. The presented studies here suggest that multiple injections of IL13-MSC are superior over a single injection (Figs. 3, 4 , and 5 versus Figs. 6 and 7) . Although this approach solves the issue of the limited local action of IL13-MSC grafting, one should take caution with multiple cellular injections in the CNS, especially when considering human applications in future. However, as to date the exact working mechanism of cellular therapies in the CNS is largely unresolved, in addition to the direct action of IL13, we previously already suggested that MSC graft-induced inflammatory responses (in this study the introduction of M2 polarised macrophages into the CNS) may lie at the basis of observed neuroprotective and/or regenerative responses [31] .
Conclusions
With this study, we propose a novel approach for effective modulation of detrimental in vivo inflammatory responses in the CNS, where IL13 production by grafted MSC and potentially aided by the appearance of alternatively activated microglia and macrophages at the MSC graft site, induces microglial quiescence and subsequent protection against oligodendrocyte death and demyelination in the CPZ mouse model for CNS inflammation and demyelination. In this context, we believe our experimental approach to be worthy of further evaluation in clinically relevant mouse models of neurotrauma displaying a gradual increase in inflammatory responses, e.g. models of spinal cord injury or stroke. 
